March 8, 2011

San Francisco Business Times

Plexxikon starts mid-stage Hodgkin trial

Plexxikon Inc., which last week said it will be sold to Daiichi Sankyo Co. for as much as $935 million, has started treating Hodgkin lymphoma patients in a mid-stage trial.

The Berkeley biotech drug developer has drawn much attention for the late-stage melanoma-fighting drug PLX-4032, but the 30-patient Phase II trial in Hodgkin lymphoma patients is with a drug called PLX-3397.

The goal of the trial is to judge the efficacy of orally administered PLX-3397, as measured by overall response rate, as well as the duration of the response, the disease control rate, progression-free survival, response biomarkers and overall safety.

It is the first of several planned proof-of concept trials with the drug, which is designed to block two cell types believed to mediate the progression of Hodgkin lymphoma tumors, that Plexxikon plans to start this year in recurrent glioblastoma multiforme, mutated relapsed acute myelogenous leukemia and metastatic breast cancer.